Abstract
Background: The kinetics of high sensitivity cardiac troponin T (hs-cTnT) levels after elective, biphasic, direct-current cardioversion for persistent atrial fibrillation/flutter remains unknown. Methods: We examined hs-cTnT kinetics in 24 patients at baseline and at 2, 6 and 24 hours post-cardioversion, and again at 7 and 30 days. We also examined levels of creatine kinase, aspartate aminotransferase, lactate dehydrogenase, brain natriuretic peptide (BNP), and high sensitivity C-reactive protein (hs-CRP). Results: Median (25th, 75th interquartiles) baseline hs-cTnT concentration was 19.8 (10.4, 35.2) ng/L with 14 patients presenting with levels above the 99th percentile (13 ng/L). Hs-cTnT levels did not change significantly over time although they tended to decrease by 30 days, 18.8 ng/L (12.5, 23.3). There was no significant rise in other markers of myocardial injury. Similarly, BNP and hs-CRP levels were elevated at baseline and tended to decrease over time. Conclusions: Patients with persistent atrial fibrillation/flutter have elevated hs-cTnT levels, as part of a general rise in biomarkers such as BNP and hs-CRP, without a further rise after cardioversion. After cardioversion, there is a gradual nonsignificant decrease in biomarker levels over time, and thus a rise in hs-cTnT levels should not be attributed to cardioversion.
| Original language | English |
|---|---|
| Pages (from-to) | 607-611 |
| Number of pages | 5 |
| Journal | Israel Medical Association Journal |
| Volume | 17 |
| Issue number | 10 |
| State | Published - 1 Oct 2015 |
| Externally published | Yes |
Keywords
- Atrial fibrillation
- Atrial flutter
- Biomarkers
- Cardioversion
- High sensitivity cardiac Troponin T levels (hs-cTnT)
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'High sensitivity cardiac troponin t levels after elective cardioversion for Atrial fibrillation/flutter'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver